Multiple media channels, both national and international, have echoed a study published by Robert E. Coleman (University of Sheffield) in the Lancet Oncology and which involved Roger Gomis (IRB Barcelona). The work allows early detection of patients who could benefit from zoledronic acid and those who should avoid it. Such early detection would thus accelerate the administration of the first preventive treatment for metastasis.
Link to JANO
Link to La Vanguardia
Link to EFE Futuro
Link to BioTech
Link to Medindia
Link to Medical Xpress
Link to ecancer
Israel Ramos is a drug discovery professional specialised in in vitro assay development support to research programs and compound characterisation. With his more than 15 years of experience in the pharmaceutical industry, he is currently working at the at IRB Barcelona Innovation department as Technology Transfer Consultant. Israel provides support to IRB Barcelona researchers by giving advice about the applicability of potential drug candidates based on IRB Barcelona discoveries.
This research will help to identify those genes that play a key role in the initiation of metastasis
Metastasis causes 90% of cancer related deaths
It is estimated that one in four people will require brain treatment at some point. While there are drug candidates for most diseases of the brain, the blood-brain barrier (BBB) poses an impassable obstacle for most of these compounds and a bottleneck for the delivery of drugs that could cure these patients.
